Duragran™ allows for more uniformity and precise control of targeted particle sizes while providing production time and cost savings
The Duragran™ patented process eliminates the need for extrusion and spheronization for high API-loaded drug particulates by using our fluid bed processing technology that combines the particle sizing and coating processes to create controlled-release beads/granules of uniform and narrow particle size range or the need to layer product onto a uniform sized sugar bead.
Duragran™ allows us to create controlled release beadlets/granules of uniform and narrow particle size range without the use of spheronization/extrusion equipment or the need to layer product onto a uniform sized sugar bead.
Duragran™ for more uniformity and targeted sizing
Duragran™ creates granules of more uniform particle size with easily modified process parameters that can be used to target a desired particle size that standard wet granulation processes cannot attain. The technology can be applied to controlled-release formulations and to create taste-masked, orally disintegrating tablet formulations.
Duragran™ provides many benefits by reducing:
- Overall production costs
- Energy requirements
- Quality Unit in-process monitoring
Speak With An Expert
Nathan Dormer
Director, Drug Product Development
Nathan Dormer, Ph.D., is the Senior Director of Drug Product Development & Site Leader at Adare Pharma Solutions and is responsible for pharmaceutical development activities at Adare’s facilities, supporting a team of formulation scientists and analysts. He is a pharmaceutical scientist and bioengineer by training, with more than 16 years of experience developing microsphere-based solid oral and parenteral/implantable dosage forms in academic, innovator, and CDMO settings. Dr. Dormer earned his B.S. in Chemical Engineering and his Ph.D. (w/Honors) in Bioengineering from The University of Kansas while receiving NIH-sponsored Pharmaceutical Biotech Training.